Back to stock research

Verified earnings summary

Research updated: Jul 12, 2026, 12:00 AM UTC

GILD Q1 2026

Gilead's first-quarter 2026 results showed growth in its base business led by HIV, Trodelvy and Livdelzi, with Yeztugo launch progress and substantial pipeline investment and acquisition activity.

This page provides a source-verified release summary. It does not display a normalized metric table or post-earnings market reaction until those fields are independently verified.

Constructive signals after the release

  • Biktarvy leadership and Yeztugo adoption can sustain treatment and prevention growth.
  • Trodelvy demand and acquired cell-therapy and antibody-drug-conjugate assets can diversify the portfolio.
  • Livdelzi uptake can add a new growth leg alongside established antiviral franchises.

Risks that still need monitoring

  • HIV concentration

    Heavy reliance on HIV leaves earnings exposed to competition, payer pressure and patent transitions.

  • Acquisition and IPR&D

    Large acquisitions and acquired research charges can consume capital without producing approved products.

  • Cell-therapy competition

    Manufacturing complexity and intense competition can pressure patient access and cell-therapy sales.

Primary sources

Gilead Sciences Announces First Quarter Financial ResultsGilead Sciences, Inc. · earningsVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Published: 5/7/2026, 12:00:00 AM

Open original source
Gilead Sciences, Inc. Investor RelationsGilead Sciences, Inc. · companyVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Open original source
Gilead SEC filings and company factsU.S. Securities and Exchange Commission · filingVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Published: 5/7/2026, 12:00:00 AM

Open original source

Continue research

Open risk researchReturn to full stock research